Accessibility Menu

MabCure

(OTC) MBCI

Current Price$0.00
Market Cap$19.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-94%
1 Year+200%
1 Month+0%

MabCure Financials at a Glance

Market Cap

$19.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$500.00K

Net Income (TTM)

-$12.45M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-9.05 (Low)

Price

$0.00

Volume

25

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jul 16, 2024

MBCI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MabCure

Industry

Biotechnology

Headquarters

White Plains, NY 10605, US

MBCI Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-141.95%

Net Income Margin

-2490.30%

Return on Equity

-127.05%

Return on Capital

-17.16%

Return on Assets

-258.80%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

64.36M

Volume

25

Avg. Volume

936.677

Financials (TTM)

Gross Profit

$500.00K

Operating Income

-$708.92K

EBITDA

-$12.05M

Operating Cash Flow

-$61.39K

Capital Expenditure

$0.00

Free Cash Flow

-$61.39K

Cash & ST Invst.

$146.44K

Total Debt

$261.16K

MabCure Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2011YOY CHG

Revenue

$500.00K

N/A

Gross Profit

$500.00K

N/A

Gross Margin

100.00%

N/A

Market Cap

$19.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.43K

N/A

Employees

3

N/A

Net Income

-$11.19M

-1658.7%

EBITDA

-$11.17M

-4782.1%

Quarterly Fundamentals

Name
Q4 2011YOY CHG

Total Cash

$146.44K

+4188.0%

Total Debt

$261.16K

+40.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$261.16K

+54.0%

Return on Assets

-2.59%

N/A

Return on Invested Capital

-18.31%

N/A

Free Cash Flow

$145.25K

+247.2%

Operating Cash Flow

$145.25K

+261.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SKPISky Petroleum, Inc.
$0.00+0.00%
BPIGFBPI Energy Holdings, Inc
$0.00+0.00%
GSLOGo Solar USA, Inc.
$0.00+0.00%
SUNWQSunworks, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$72.64-0.06%
CLSKCleanSpark
$12.36-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$39.95+0.06%
PLTRPalantir Technologies
$130.04+0.03%

Questions About MBCI

What is the current price of MabCure?

MabCure is trading at $0.00 per share.

What is the 52-week range for MabCure?

Over the past 52 weeks, MabCure has traded between $0.00 and $0.00.

How much debt does MabCure have?

MabCure total debt is unavailable.

How much cash does MabCure have on hand?

MabCure does not have cash on hand data available.

What is MabCure’s dividend yield?

MabCure does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.